Skip to main content

Advertisement

Table 1 Demographic features, clinical records, and immunomodulatory therapy of the AR population

From: Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis

Parameters csDMARD n = 73 cs+bDMARD n = 48
1–5 years n = 18 > 5–9 years n = 37 ≥ 10 years n = 18 1–5 years n = 10 > 5–9 years n = 25 ≥ 10 years n = 13
Gender (F/M) 17/01 35/02 15/03 09/01 23/02 13/00
Age (years) 58 (31–78) 53 (26–86) 49 (23–81) 55 (28–75) 60 (40–82) 54 (29–80)
Disease duration (months) 99 (12–432) 114 (12–348) 84 (12–480) 210 (96–298) 144 (72–370) 168 (96–288)
csDMARD dose
 MTX (2.5– 25 mg/week) 17 mg (14/18) 16 mg (35/37) 18 mg (12/18) 23 mg (05/10) 17 mg (14/25) 17 mg (04/13)
 LEF (standard dose/day) 20 mg (06/18) 20 mg (19/37) 20 mg (09/18) 20 mg (05/10) 20 mg (12/25) 20 mg (06/13)
 SSZ (1000–3000 mg/day) 1500 mg (02/18) 2300 mg (03/18) 1000 mg (02/25) 1200 mg (05/13)
 AML (150–400 mg/day) 275 mg (04/18) 340 mg (05/37) 150 mg/day (01/25) 275 mg/day (02/13)
 AZA (2–3 mg/kg/day) 150 mg (01/10)
 CYC (3–5 mg/kg/day) 200 mg (01/13)
bDMARD dose
 ADA (standard dose/eow) 40 mg (01/10) 40 mg (02/25) 40 mg (01/13)
 CTZ (standard dose/month) 400 mg (02/10) 400 mg (01/13)
 ETN (standard dose/week) 50 mg (05/10) 50 mg (05/25) 50 mg (04/13)
 GOL (standard dose/month) 50 mg (02/25) 50 mg (03/13)
 IFX (3–5 mg/kg/e8w) 300 mg (01/10) 233 mg (06/25)
 TCZ (8 mg/kg/month) 496 mg (05/25) 480 mg (02/13)
 ABT (10 mg/kg/month) 750 mg (03/25) 750 mg (01/13)
 RTX (standard dose/e6m) 1000 mg (01/10) 1000 mg (02/25) 1000 mg (01/13)
GC
 PDN (2.5–40 mg/day) 7.5 mg (04/18) 13.6 mg (06/37) 8.2 mg (07/18) 6.7 mg (03/10) 10.8 mg (06/25) 7.0 mg (05/13)
  1. Age is expressed as median (min-max). Disease duration in months is expressed as median (min-max). Immunomodulatory therapeutic dosages are provided for each drug and as mean dose/group
  2. csDMARD conventional synthetic disease-modifying anti-rheumatic drugs, cs+bDMARD combined conventional synthetic and biological disease-modifying anti-rheumatic drugs, CG glucocorticoid, F female, M male, MTX methotrexate, LEF leflunomide, SSZ sulfasalazine, AML anti-malarial drugs (hydroxychloroquine and chloroquine phosphate), AZA azathioprine, CYC ciclosporin, ADA adalimumab, CTZ certolizumab, ETN etanercept, GOL golimumab, IFX infliximab, TCZ tocilizumab, ABT abatacept, RTX rituximab, PDN prednisone, eow every other week, e8w every 8 weeks, e6m every 6 months